Reviving the use of aldosterone inhibitors in treating hypertension in obesity

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Obesity is a multifactorial disease associated with hypertension. In the obese population, the incidence of hypertension is high and resistant hypertension is commonly observed. Mechanisms to explain the resistance to current antihypertensive treatments are still poorly understood. Emerging knowledge of the role of aldosterone in controlling blood pressure in obesity may have therapeutic benefit. Mineralocorticoid receptor (MR) inhibitors are currently used as the fourth line of treatment. Clinical studies summarized in this short review suggest that MR antagonists have a strong efficacy in decreasing blood pressure in the hypertensive obese population and could be used as a primary antihypertensive in obesity.

Original languageEnglish (US)
Pages (from-to)R1065-R1067
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume309
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

Aldosterone
Obesity
Hypertension
Antihypertensive Agents
Blood Pressure
Mineralocorticoid Receptor Antagonists
Mineralocorticoid Receptors
Population
Incidence
Therapeutics

Keywords

  • Aldosterone
  • Hypertension
  • Obesity

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Reviving the use of aldosterone inhibitors in treating hypertension in obesity. / Huby, Anne Cecile; Belin de Chantemele, Eric Jacques.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 309, No. 9, 01.01.2015, p. R1065-R1067.

Research output: Contribution to journalReview article

@article{f88bead56e2b48d28a29fada0f4e9547,
title = "Reviving the use of aldosterone inhibitors in treating hypertension in obesity",
abstract = "Obesity is a multifactorial disease associated with hypertension. In the obese population, the incidence of hypertension is high and resistant hypertension is commonly observed. Mechanisms to explain the resistance to current antihypertensive treatments are still poorly understood. Emerging knowledge of the role of aldosterone in controlling blood pressure in obesity may have therapeutic benefit. Mineralocorticoid receptor (MR) inhibitors are currently used as the fourth line of treatment. Clinical studies summarized in this short review suggest that MR antagonists have a strong efficacy in decreasing blood pressure in the hypertensive obese population and could be used as a primary antihypertensive in obesity.",
keywords = "Aldosterone, Hypertension, Obesity",
author = "Huby, {Anne Cecile} and {Belin de Chantemele}, {Eric Jacques}",
year = "2015",
month = "1",
day = "1",
doi = "10.1152/ajpregu.00133.2015",
language = "English (US)",
volume = "309",
pages = "R1065--R1067",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "9",

}

TY - JOUR

T1 - Reviving the use of aldosterone inhibitors in treating hypertension in obesity

AU - Huby, Anne Cecile

AU - Belin de Chantemele, Eric Jacques

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Obesity is a multifactorial disease associated with hypertension. In the obese population, the incidence of hypertension is high and resistant hypertension is commonly observed. Mechanisms to explain the resistance to current antihypertensive treatments are still poorly understood. Emerging knowledge of the role of aldosterone in controlling blood pressure in obesity may have therapeutic benefit. Mineralocorticoid receptor (MR) inhibitors are currently used as the fourth line of treatment. Clinical studies summarized in this short review suggest that MR antagonists have a strong efficacy in decreasing blood pressure in the hypertensive obese population and could be used as a primary antihypertensive in obesity.

AB - Obesity is a multifactorial disease associated with hypertension. In the obese population, the incidence of hypertension is high and resistant hypertension is commonly observed. Mechanisms to explain the resistance to current antihypertensive treatments are still poorly understood. Emerging knowledge of the role of aldosterone in controlling blood pressure in obesity may have therapeutic benefit. Mineralocorticoid receptor (MR) inhibitors are currently used as the fourth line of treatment. Clinical studies summarized in this short review suggest that MR antagonists have a strong efficacy in decreasing blood pressure in the hypertensive obese population and could be used as a primary antihypertensive in obesity.

KW - Aldosterone

KW - Hypertension

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84946032137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946032137&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00133.2015

DO - 10.1152/ajpregu.00133.2015

M3 - Review article

C2 - 26157057

AN - SCOPUS:84946032137

VL - 309

SP - R1065-R1067

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 9

ER -